Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Whitton

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
BMJ Open|April 2, 2020
Cohort profile: the Brain and Mind Centre <i>Optymise</i> cohort: tracking multidimensional outcomes in young people presenting for mental healthcareJoanne S Carpenter, Frank Iorfino, Shane Cross, et al.
Translational Psychiatry|November 6, 2021
Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedoniaSara Costi, Laurel S Morris, Abigail Collins, et al.
Molecular Psychiatry|November 3, 2018
Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorderAaron Tan, Sara Costi, Laurel S Morris, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 14, 2021
Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)Diego A Pizzagalli, Moria Smoski, Yuen-Siang Ang, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 17, 2020
Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)Diego A Pizzagalli, Moria Smoski, Yuen-Siang Ang, et al.
Journal of Affective Disorders|July 19, 2023
Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS studySabrina M Darrow, Diego A Pizzagalli, Moria Smoski, et al.
Biological Psychiatry|February 6, 2019
Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical TrialAlexis E Whitton, Christian A Webb, Daniel G Dillon, et al.
Nature Medicine|April 2, 2020
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedoniaAndrew D Krystal, Diego A Pizzagalli, Moria Smoski, et al.
JAMA Network Open|October 31, 2025
Brief Digital Interventions for Psychological Distress: An AI-Enhanced Response-Adaptive Randomized Clinical TrialJill Newby, Sunil Gupta, Leonard Hoon, et al.
Health Technology Assessment (Winchester, England)|November 27, 2020
Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCTJonathan M Batchelor, Kim S Thomas, Perways Akram, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
BMJ Open|April 2, 2020
Cohort profile: the Brain and Mind Centre <i>Optymise</i> cohort: tracking multidimensional outcomes in young people presenting for mental healthcareJoanne S Carpenter, Frank Iorfino, Shane Cross, et al.
Translational Psychiatry|November 6, 2021
Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedoniaSara Costi, Laurel S Morris, Abigail Collins, et al.
Molecular Psychiatry|November 3, 2018
Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorderAaron Tan, Sara Costi, Laurel S Morris, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 14, 2021
Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)Diego A Pizzagalli, Moria Smoski, Yuen-Siang Ang, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 17, 2020
Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)Diego A Pizzagalli, Moria Smoski, Yuen-Siang Ang, et al.
Journal of Affective Disorders|July 19, 2023
Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS studySabrina M Darrow, Diego A Pizzagalli, Moria Smoski, et al.
Biological Psychiatry|February 6, 2019
Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical TrialAlexis E Whitton, Christian A Webb, Daniel G Dillon, et al.
Nature Medicine|April 2, 2020
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedoniaAndrew D Krystal, Diego A Pizzagalli, Moria Smoski, et al.
JAMA Network Open|October 31, 2025
Brief Digital Interventions for Psychological Distress: An AI-Enhanced Response-Adaptive Randomized Clinical TrialJill Newby, Sunil Gupta, Leonard Hoon, et al.
Health Technology Assessment (Winchester, England)|November 27, 2020
Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCTJonathan M Batchelor, Kim S Thomas, Perways Akram, et al.
Pageof 9